 The primary purpose of this study is to assess the safety and feasibility of giving TNFeradeTM with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection. TNFeradeTM is a replication deficient E1, E3 and E4 deleted adenovirus vector containing the gene for TNF-alpha controlled by a radiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a potent cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFeradeTM is a novel way of selective delivery of TNF-alpha to tumor cells. 